Regenxbio shares new Duchenne gene therapy data ahead of big readout next year
Regenxbio has biomarker data on the first patient younger than 4 years old dosed with its Duchenne muscular dystrophy gene therapy, showing that the patient expressed levels of a shortened version of a key muscle ...
Regenxbio has biomarker data on the first patient younger than 4 years old dosed with its Duchenne muscular dystrophy gene therapy, showing that the patient expressed levels of a shortened version of a key muscle ...
